首页> 美国卫生研究院文献>Journal of Clinical Medicine >Role of Endogenous Regulators of Hem- And Lymphangiogenesis in Corneal Transplantation
【2h】

Role of Endogenous Regulators of Hem- And Lymphangiogenesis in Corneal Transplantation

机译:内源性调节血红素和淋巴管生成在角膜移植中的作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Under normal conditions, the cornea, being the transparent “windscreen” of the eye, is free of both blood and lymphatic vessels. However, various diseases of the eye, like infections, can interfere with the balance between promoting and inhibiting factors, which leads to ingrowth of blood and lymphatic vessels. The newly formed lymphatic vessels increase the risk of graft rejection after subsequent corneal transplantation. Corneal transplantation is one of the most commonly performed transplantations worldwide, with more than 40,000 surgeries per year in Europe. To date, various anti-hem- and anti-lymphangiogenic treatment strategies have been developed specifically for the corneal vascular endothelial growth factor (VEGF) pathway. Currently, however, no treatment strategies are clinically available to specifically modulate lymphangiogenesis. In this review, we will give an overview about endogenous regulators of hem- and lymphangiogenesis and discuss potential new strategies for targeting pathological lymphangiogenesis. Furthermore, we will review recently identified modulators and demonstrate that the cornea is a suitable model for the identification of novel endogenous modulators of lymphangiogenesis. The identification of novel modulators of lymphangiogenesis and a better understanding of the signaling pathways involved will contribute to the development of new therapeutic targets for the treatment of pathological lymphangiogenesis. This, in turn, will improve graft rejection, not only for the cornea.
机译:在正常情况下,角膜是眼睛的透明“挡风玻璃”,没有血液和淋巴管。但是,眼部各种疾病(如感染)会干扰促进和抑制因子之间的平衡,从而导致血液和淋巴管向内生长。新形成的淋巴管增加了后续角膜移植后移植排斥的风险。角膜移植是世界上最常进行的移植之一,在欧洲每年有40,000多次手术。迄今为止,已经针对角膜血管内皮生长因子(VEGF)途径专门开发了多种抗血红素和抗淋巴管生成的治疗策略。但是,目前,尚无临床上可用于特异性调节淋巴管生成的治疗策略。在这篇综述中,我们将概述血肿和淋巴管生成的内源性调节剂,并讨论针对病理性淋巴管生成的潜在新策略。此外,我们将回顾最近发现的调节剂,并证明角膜是用于鉴定淋巴管生成的新型内源性调节剂的合适模型。新型淋巴管生成调节剂的鉴定和对所涉及的信号通路的更好理解将有助于开发用于病理性淋巴管生成的新治疗靶标。反过来,这不仅会改善角膜,还将改善移植排斥。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号